Drug-drug interactions in patients co-infected with HCV and HIV

JAMA - Journal of the American Medical Association

Volumn 314, Issue 2, 2015, Pages 186-

  Nozaki, Yuichi ^a   Yanase, Mikio ^a   Masaki, Naohiko ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYTOCHROME P450; LEDIPASVIR; MULTIDRUG RESISTANCE PROTEIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; URIDINE PHOSPHATE;

CD4 LYMPHOCYTE COUNT; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LETTER; MIXED INFECTION; PILOT STUDY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; MALE;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; URIDINE MONOPHOSPHATE;

EID: 84937250129     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.6618     Document Type: Letter

References (1)

1. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232-1239.